SCHEMBL1019782

SCHEMBL1019782

CCN(CCN(CC)S(=O)(=O)c1cccs1)c1nc(Cc2ccccc2C)ns1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 8/20 0.35
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
PGGT1B P53609 1/20 0.34
LMNA P02545 2/20 0.34
MAPT P10636 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
HTT P42858 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
HPGD P15428 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HSD17B10 Q99714 1/20 0.32
TP53 P04637 1/20 0.32
TSHR P16473 1/20 0.31
KDM4E B2RXH2 1/20 0.31
GAA P10253 1/20 0.31
SQLE Q14534 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1021265 0.90 NPC1 (0.35) ALDH1A1FNTAFNTBPGGT1BLMNA
SCHEMBL1021642 0.88 ALDH1A1 (0.37) ALDH1A1FNTAFNTBPGGT1BLMNA
SCHEMBL1021855 0.87 FNTA (0.41) ALDH1A1FNTAFNTBPGGT1BMAPT
SCHEMBL1022524 0.86 CNR2 (0.39) ALDH1A1FNTAFNTBPGGT1BLMNA
SCHEMBL1020807 0.83 SQLE (0.36) ALDH1A1FNTAFNTBPGGT1BLMNA
SCHEMBL1019501 0.83 TAS2R14 (0.38) ALDH1A1FNTAFNTBPGGT1BLMNA
SCHEMBL1019785 0.83 NPC1 (0.35) ALDH1A1FNTAFNTBPGGT1BMAPT
SCHEMBL1019792 0.83 MEN1 (0.35) ALDH1A1FNTAFNTBPGGT1BLMNA
SCHEMBL2008691 0.81 TAS2R14 (0.42) RAB9AALDH1A1LMNAHTTSMN1; SMN2
SCHEMBL1018654 0.81 ALDH1A1 (0.38) RAB9AALDH1A1LMNAMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US claimed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP claimed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US claimed
US-7960556-B2 Thiadiazole derivatives for the treatment of neuro-degenerative diseases NV REMYND (BE) 2011-06-14 US disclosed
EP-2094677-B1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES REMYND NV (BE) 2011-01-12 EP disclosed
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES NV REMYND (BE) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144709-A1 THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES SNCA, PARK7, PRNP RAB9A 1244/4885ALDH1A1 608/4885FNTA 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.